DDInter1397 DDInter826
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting hypoglycemia that is often observed with blood glucose-lowering agents. Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip®.
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glipizide
Paroxetine {u} (Compound) downregulates {v} (Gene) MIF
MIF {u} (Gene) is downregulated by {v} (Compound) Glipizide
Paroxetine {u} (Compound) upregulates {v} (Gene) GRN
GRN {u} (Gene) is downregulated by {v} (Compound) Glipizide
Paroxetine {u} (Compound) causes {v} (Side Effect) Retinal haemorrhage
Retinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Glipizide
Paroxetine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glyburide
Glyburide {u} (Compound) resembles {v} (Compound) Glipizide
Paroxetine {u} (Compound) downregulates {v} (Gene) MIF
MIF {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Glipizide
Paroxetine {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Glipizide
Paroxetine {u} (Compound) downregulates {v} (Gene) PCNA
PCNA {u} (Gene) is regulated by {v} (Gene) PPARG
PPARG {u} (Gene) is bound by {v} (Compound) Glipizide
Paroxetine {u} (Compound) upregulates {v} (Gene) GRN
GRN {u} (Gene) regulates {v} (Gene) CEBPB
CEBPB {u} (Gene) is downregulated by {v} (Compound) Glipizide
Paroxetine {u} (Compound) causes {v} (Side Effect) Retinal haemorrhage
Retinal haemorrhage {u} (Side Effect) is caused by {v} (Compound) Fluoxetine
Fluoxetine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Paroxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glipizide (Compound)
Paroxetine (Compound) downregulates MIF (Gene) and MIF (Gene) is downregulated by Glipizide (Compound)
Paroxetine (Compound) upregulates GRN (Gene) and GRN (Gene) is downregulated by Glipizide (Compound)
Paroxetine (Compound) causes Retinal haemorrhage (Side Effect) and Retinal haemorrhage (Side Effect) is caused by Glipizide (Compound)
Paroxetine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glyburide (Compound) and Glyburide (Compound) resembles Glipizide (Compound)
Paroxetine (Compound) downregulates MIF (Gene) and MIF (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Glipizide (Compound)
Paroxetine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Gliclazide (Compound) and Gliclazide (Compound) resembles Glipizide (Compound)
Paroxetine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is regulated by PPARG (Gene) and PPARG (Gene) is bound by Glipizide (Compound)
Paroxetine (Compound) upregulates GRN (Gene) and GRN (Gene) regulates CEBPB (Gene) and CEBPB (Gene) is downregulated by Glipizide (Compound)
Paroxetine (Compound) causes Retinal haemorrhage (Side Effect) and Retinal haemorrhage (Side Effect) is caused by Fluoxetine (Compound) and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide